Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer.

Authors:

Abstract
1002 Background: Abemaciclib is a selective inhibitor of CDK4 & 6 that is dosed on a continuous schedule and is approved for the treatment of HR+, HER2- advanced breast cancer (ABC) as monotherapy and in combination with fulvestrant (F). In the intent-to-treat (ITT) population in the MONARCH 2 study, abemaciclib in combination with F demonstrated improved progression-free survival (PFS) and objective response rate (ORR) compared to placebo (P) + F (16.4 vs 9.3 months; hazard ratio [HR] .553; 95% CI: .449, .681; p < .0000001; ORR in measurable disease 48.1% vs 21.3%; p < .001). Here, we compare the efficacy and safety of abemaciclib + F vs P + F in the pre/peri-menopausal subgroup. Methods: MONARCH 2 was a Phase 3 randomized, double-blind, placebo-controlled study of abemaciclib + F vs P + F in pts with HR+, HER2- ABC that progressed on ET. Key eligibility criteria were: pre/peri- and post-menopausal women with HR+, HER2- ABC (pre/peri-menopausal pts received a GnRH agonist); ECOG PS ≤ 1; progression on (neo)adjuvant ET, ≤12 months from end of adjuvant ET, or on first line ET for metastatic disease; ≤1 line of ET; no prior chemotherapy for metastatic disease. Pts received orally administered abemaciclib 150 mg twice daily + 500 mg F (per label) or P + F. Primary objective was investigator-assessed PFS. Secondary objectives included ORR, clinical benefit rate, disease control rate, duration of response, safety and tolerability. Results: 114 pre/peri-menopausal pts were randomized 2:1 to abemaciclib + F (N = 72) and P + F (N = 42) arms. 57 PFS events were observed. Median PFS was not reached for the abemaciclib + F arm and was 10.5 months for the P + F arm (HR, .446; 95% CI: .264, .754; p = .002). In pts with measurable disease (n = 79, 69.3%), ORR was significantly higher in the abemaciclib + F arm: 60.8% (3.9% complete response [CR]) vs 28.6% (0% CR; p = .006). The most frequent adverse events (any grade) for abemaciclib + F vs P + F were diarrhea (87.3% vs 23.8%), neutropenia (59.2% vs 7.1%) and leukopenia (43.7% vs 4.8%). Conclusions: Abemaciclib + F in combination with a GnRH agonist significantly improved PFS and ORR, and had a generally tolerable safety profile in pre/peri-menopausal women with HR+, HER2- ABC. Clinical trial information: NCT02107703.